Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Paclitexel-induced neuropathic pain - McGill study may lead to the identification of novel targets for analgesia and improved cancer therapeutics

14 Apr 04

DailyUpdates 14th April: Neuropathic pain affects 26 million patients including a sub-population of cancer patients being treated with cytotoxics. McGill researchers have published the results of a study looking at neuropathic pain in various strains of mice. These data show that neuropathic pain has a genetic component suggested to be equally relevant to paclitaxel and surgically-induced pain. The study also advances the use of paclitaxel-induced hyperalgesia as a model for the development o
LeadDiscovery

Novo Nordisk publish data demonstrating proof of concept for potassium channel openers as treatments of diabetes

13 Apr 04

DailyUpdates 13th April: According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. Approximately 10-15% of these patients suffer type 1 diabetes. Novo Nordisk have shown that their Kir6.2/SUR1 channel opener, NN414 is able to preserve beta-cell function and reduction of insulitis presumable through the induction of "beta-cell rest".
LeadDiscovery

Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis

08 Apr 04

DailyUpdates 8th April: An estimated 5 million individuals suffer from rheumatoid arthritis in the Western world. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, their clinical benefit for rheumatoid arthritis often diminishes with time. This, the severe rebounds observed following the withdrawal of corticosteroids, and long-term systemic side effects associated with corticosteroids limits their use in the treatment of rheumatoid arthritis. Rese
LeadDiscovery

Eli Lilly's Duloxetine set to become the first widely used therapeutic treatment of stress urinary incontinence

07 Apr 04

DailyUpdates 7th April: A recent survey of community-dwelling women in France, Germany, Spain and the UK found that 35% women suffer urinary incontinence, the most prevalent form of which was stress urinary incontinence. The findings also revealed that two-thirds of women affected with urinary incontinence never consulted a health care professional for treatment. The perceived and real lack of pharmaceutical options for the treatment of stress urinary incontinence is a major factor contributing
LeadDiscovery

New data shows that intensive treatment of diabetes may lower coexistent hypertension and delay renal dialysis by up to 20 years

06 Apr 04

DailyUpdates 6th April: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. In a recent study Glasgow Royal Infirmary researchers report that intensive treatment slowed progression of renal disease within 2 years in patients with established diabetic nephropathy and predict that this approach may delay the onset of dialysis b
LeadDiscovery

Links between obesity/diabetes & Alzheimer disease: Diet-induced insulin resistance shown to increase CNS beta-amyloid levels and worsens cognition in a model of Alzheimer disease

05 Apr 04

DailyUpdates 5th April: There is growing evidence of a link between type-2 diabetes/obesity and Alzheimer disease. Researchers now report that diet-induced insulin resistance increases beta amyloid generation, amyloid plaque burden in the brain and behavioural impairment in a model of Alzheimer disease.
Leaddiscovery

Type 2 diabetes as a risk factor for Alzheimer's disease - defective insulin-degrading enzyme as an etiological link?

02 Apr 04

DailyUpdates 2nd April: There is growing evidence that type-2 diabetes is a risk factor for Alzheimer disease. In their April American Journal of Pathology article Brigham and Women's Hospital researchers add further evidence to support defects in insulin-degrading enzyme activity as a potential cause of this phenomenon. This and similar data argues for the development of cross-indication treatments of type-2 diabetes and Alzheimer disease and GSK-3 inhibitors may fit the bill.
LeadDiscovery

GREES publish new recommendations on the clinical development of disease modifying osteoarthritis drugs (DMOADs)

01 Apr 04

DailyUpdates 1st April: Osteoarthritis is the most common form of arthritis and is estimated to affect over 73 million people in the seven major pharmaceutical markets. Disease modifying osteoarthritis drugs (DMOADs) currently represent the ‘holy grail’ in the treatment of osteoarthritis. The Group for the Respect of Ethics and Excellence in Science (GREES) have now published recommendations on the clinical development of DMOADs.
LeadDiscovery

Merck & Co develop new leads for the treatment of bipolar disorder through the development of a new HTS assay of inositol monophosphatase inhibitors

31 Mar 04

DailyUpdates 31st March: Bipolar disorder affects over 2 million people in the US alone. Lithium, which inhibits inositol monophosphatase, has long been a first line mood stabilizer used in the treatment of this condition. Merck & Co have now developed a new cell-based HTS assay to identify novel inositol monophosphatase inhibitors which will hopefully lead to improved treatments of bipolar disorder.
LeadDiscovery

Sulfonylureas vs thiazolidinediones for the prevention of diabetic nephropathy

30 Mar 04

DailyUpdates 30th March: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. Intensive glycemic control prevents or retards microalbuminuria, an early sign of nephropathy in patients with type 2 diabetes and in a recent study Japanese researchers compare two different classes of oral antidiabetic drugs with respect to their e
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.